264 related articles for article (PubMed ID: 21345969)
1. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation.
Piali L; Froidevaux S; Hess P; Nayler O; Bolli MH; Schlosser E; Kohl C; Steiner B; Clozel M
J Pharmacol Exp Ther; 2011 May; 337(2):547-56. PubMed ID: 21345969
[TBL] [Abstract][Full Text] [Related]
2. A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.
Hale JJ; Lynch CL; Neway W; Mills SG; Hajdu R; Keohane CA; Rosenbach MJ; Milligan JA; Shei GJ; Parent SA; Chrebet G; Bergstrom J; Card D; Ferrer M; Hodder P; Strulovici B; Rosen H; Mandala S
J Med Chem; 2004 Dec; 47(27):6662-5. PubMed ID: 15615513
[TBL] [Abstract][Full Text] [Related]
3. 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists.
Bolli MH; Abele S; Binkert C; Bravo R; Buchmann S; Bur D; Gatfield J; Hess P; Kohl C; Mangold C; Mathys B; Menyhart K; Müller C; Nayler O; Scherz M; Schmidt G; Sippel V; Steiner B; Strasser D; Treiber A; Weller T
J Med Chem; 2010 May; 53(10):4198-211. PubMed ID: 20446681
[TBL] [Abstract][Full Text] [Related]
4. SAR studies of 3-arylpropionic acids as potent and selective agonists of sphingosine-1-phosphate receptor-1 (S1P1) with enhanced pharmacokinetic properties.
Yan L; Huo P; Hale JJ; Mills SG; Hajdu R; Keohane CA; Rosenbach MJ; Milligan JA; Shei GJ; Chrebet G; Bergstrom J; Card D; Mandala SM
Bioorg Med Chem Lett; 2007 Feb; 17(3):828-31. PubMed ID: 17092714
[TBL] [Abstract][Full Text] [Related]
5. Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow.
Maeda Y; Seki N; Sato N; Sugahara K; Chiba K
Int Immunol; 2010 Jun; 22(6):515-25. PubMed ID: 20497959
[TBL] [Abstract][Full Text] [Related]
6. Sphingosine-1-phosphate (S1P) displays sustained S1P1 receptor agonism and signaling through S1P lyase-dependent receptor recycling.
Gatfield J; Monnier L; Studer R; Bolli MH; Steiner B; Nayler O
Cell Signal; 2014 Jul; 26(7):1576-88. PubMed ID: 24704119
[TBL] [Abstract][Full Text] [Related]
7. A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis.
Quancard J; Bollbuck B; Janser P; Angst D; Berst F; Buehlmayer P; Streiff M; Beerli C; Brinkmann V; Guerini D; Smith PA; Seabrook TJ; Traebert M; Seuwen K; Hersperger R; Bruns C; Bassilana F; Bigaud M
Chem Biol; 2012 Sep; 19(9):1142-51. PubMed ID: 22999882
[TBL] [Abstract][Full Text] [Related]
8. Discovery of S1P agonists with a dihydronaphthalene scaffold.
Kurata H; Kusumi K; Otsuki K; Suzuki R; Kurono M; Takada Y; Shioya H; Komiya T; Mizuno H; Ono T; Hagiya H; Minami M; Nakade S; Habashita H
Bioorg Med Chem Lett; 2011 Jul; 21(13):3885-9. PubMed ID: 21641216
[TBL] [Abstract][Full Text] [Related]
9. Removal of sphingosine 1-phosphate receptor-3 (S1P(3)) agonism is essential, but inadequate to obtain immunomodulating 2-aminopropane-1,3-diol S1P(1) agonists with reduced effect on heart rate.
Hamada M; Nakamura M; Kiuchi M; Marukawa K; Tomatsu A; Shimano K; Sato N; Sugahara K; Asayama M; Takagi K; Adachi K
J Med Chem; 2010 Apr; 53(8):3154-68. PubMed ID: 20337461
[TBL] [Abstract][Full Text] [Related]
10. Highly selective and potent agonists of sphingosine-1-phosphate 1 (S1P1) receptor.
Vachal P; Toth LM; Hale JJ; Yan L; Mills SG; Chrebet GL; Koehane CA; Hajdu R; Milligan JA; Rosenbach MJ; Mandala S
Bioorg Med Chem Lett; 2006 Jul; 16(14):3684-7. PubMed ID: 16682185
[TBL] [Abstract][Full Text] [Related]
11. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.
Mandala S; Hajdu R; Bergstrom J; Quackenbush E; Xie J; Milligan J; Thornton R; Shei GJ; Card D; Keohane C; Rosenbach M; Hale J; Lynch CL; Rupprecht K; Parsons W; Rosen H
Science; 2002 Apr; 296(5566):346-9. PubMed ID: 11923495
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes.
Yan L; Huo P; Doherty G; Toth L; Hale JJ; Mills SG; Hajdu R; Keohane CA; Rosenbach MJ; Milligan JA; Shei GJ; Chrebet G; Bergstrom J; Card D; Quackenbush E; Wickham A; Mandala SM
Bioorg Med Chem Lett; 2006 Jul; 16(14):3679-83. PubMed ID: 16697189
[TBL] [Abstract][Full Text] [Related]
13. A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model.
Pan S; Mi Y; Pally C; Beerli C; Chen A; Guerini D; Hinterding K; Nuesslein-Hildesheim B; Tuntland T; Lefebvre S; Liu Y; Gao W; Chu A; Brinkmann V; Bruns C; Streiff M; Cannet C; Cooke N; Gray N
Chem Biol; 2006 Nov; 13(11):1227-34. PubMed ID: 17114004
[TBL] [Abstract][Full Text] [Related]
14. Sphingosine-1-phosphate receptor type-1 agonism impairs blood dendritic cell chemotaxis and skin dendritic cell migration to lymph nodes under inflammatory conditions.
Gollmann G; Neuwirt H; Tripp CH; Mueller H; Konwalinka G; Heufler C; Romani N; Tiefenthaler M
Int Immunol; 2008 Jul; 20(7):911-23. PubMed ID: 18495625
[TBL] [Abstract][Full Text] [Related]
15. Development of a selective S1P1 receptor agonist, Syl930, as a potential therapeutic agent for autoimmune encephalitis.
Jin J; Hu J; Zhou W; Wang X; Xiao Q; Xue N; Yin D; Chen X
Biochem Pharmacol; 2014 Jul; 90(1):50-61. PubMed ID: 24780445
[TBL] [Abstract][Full Text] [Related]
16. Lymphopenia induced by a novel selective S1P(1) antagonist structurally unrelated to S1P.
Fujii Y; Ohtake H; Ono N; Hara T; Sakurai T; Takahashi S; Takayama T; Fukasawa Y; Shiozawa F; Tsukahara N; Hirayama T; Igarashi Y; Goitsuka R
Biochim Biophys Acta; 2012 Apr; 1821(4):600-6. PubMed ID: 22265714
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology of ponesimod, a selective S1P₁ receptor modulator, after uptitration to supratherapeutic doses in healthy subjects.
Hoch M; D'Ambrosio D; Wilbraham D; Brossard P; Dingemanse J
Eur J Pharm Sci; 2014 Oct; 63():147-53. PubMed ID: 25046167
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of CS-2100, a potent, orally active and S1P(3)- sparing S1P(1) agonist.
Nakamura T; Asano M; Sekiguchi Y; Mizuno Y; Tamaki K; Nara F; Kawase Y; Yabe Y; Nakai D; Kamiyama E; Urasaki-Kaneno Y; Shimozato T; Doi-Komuro H; Kagari T; Tomisato W; Inoue R; Nagasaki M; Yuita H; Oguchi-Oshima K; Kaneko R; Nishi T
Eur J Med Chem; 2012 May; 51():92-8. PubMed ID: 22405291
[TBL] [Abstract][Full Text] [Related]
19. Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses.
Wei SH; Rosen H; Matheu MP; Sanna MG; Wang SK; Jo E; Wong CH; Parker I; Cahalan MD
Nat Immunol; 2005 Dec; 6(12):1228-35. PubMed ID: 16273098
[TBL] [Abstract][Full Text] [Related]
20. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes.
Forrest M; Sun SY; Hajdu R; Bergstrom J; Card D; Doherty G; Hale J; Keohane C; Meyers C; Milligan J; Mills S; Nomura N; Rosen H; Rosenbach M; Shei GJ; Singer II; Tian M; West S; White V; Xie J; Proia RL; Mandala S
J Pharmacol Exp Ther; 2004 May; 309(2):758-68. PubMed ID: 14747617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
